Purine analogues in advanced T-cell lymphoid malignancies.
T-cell lymphomas account for 10% to 15% of all lymphoid malignancies. In advanced stages of T-cell lymphoma, single or multiagent chemotherapy and bioimmunotherapeutic agents have been used. Purine analogues have demonstrated activity in both refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma with response rates ranging from 20% to 70%. Response rates have been higher with pentostatin (60%) than with the other compounds in this class. The potential limitation to this therapy is the prolonged immunosuppression, which increases the risk of opportunistic injections in patients who are already at heightened risk for infections. Patients should be monitored closely with CD4 counts and surveillance for opportunistic infections. Future studies of purine analogues should evaluate patients who are less heavily pretreated and combination therapy with other agents such as alemtuzumab should be investigated in order to prolong the duration of disease remission.
Kurzrock
Razelle
R
Department of Bioimmunotherapy, University of Texas-M.D. Anderson Cancer Center, Houston, TX 77030, USA. rkurzroc@mdanderson.org
Ravandi
Farhad
F
D006801:Humans; D015458:Leukemia, T-Cell / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D011684:Purine Nucleosides / Q000627:therapeutic use*; D016896:Treatment Outcome
D011684:Purine Nucleosides